ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc., (“ITI”), a privately-held clinical-stage biotechnology company pioneering the study of LAMP-mediated nucleic acid-based immunotherapy, ...
ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc., a privately held clinical stage biotechnology company pioneering the study of nucleic acid immunotherapy platforms, announced today that ...
ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc. will present late-breaking preclinical data which shows that its’ investigational nucleic acid platform, UNITE, may enhance antitumor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback